PARP inhibitors are lethal to BRCA-mutant cancer cells, since they induce single strand DNA lesions, and persistent single strand DNA breaks lead to DSBs that cannot be repaired by impaired homologous recombination. The gene discussed is PARP1; the disease is cancer.